open access

Online first
Short communication
Published online: 2021-11-05
Get Citation

In-vitro mechanical behavior and in-vivo healing response of a new generation biodegradable-polymer coated thin strut sirolimus eluting stent

Paweł Gąsior1, Łukasz Pyka2, Michał Hawranek2, Michał Garbacz3, Madeline Chagnon4, Diane Beaudry4, Joanna Fluder1, Mariusz Gąsior2, Wojciech Wojakowski1, Andrzej Lekston2
DOI: 10.33963/KP.a2021.0158
·
Pubmed: 34775590
Affiliations
  1. Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
  2. 3rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland
  3. Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Center for Heart Diseases in Zabrze, Zabrze, Poland
  4. Charles River Laboratories, Montreal, Canada

open access

Online first
Short communication
Published online: 2021-11-05

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

In-vitro mechanical behavior and in-vivo healing response of a new generation biodegradable-polymer coated thin strut sirolimus eluting stent

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Short communication

Published online

2021-11-05

DOI

10.33963/KP.a2021.0158

Pubmed

34775590

Authors

Paweł Gąsior
Łukasz Pyka
Michał Hawranek
Michał Garbacz
Madeline Chagnon
Diane Beaudry
Joanna Fluder
Mariusz Gąsior
Wojciech Wojakowski
Andrzej Lekston

References (10)
  1. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47(1): 175–181.
  2. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012; 59(23): 2051–2057.
  3. Dores H, Raposo L, Campante Teles R, et al. Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry. J Invasive Cardiol. 2013; 25(7): 330–336.
  4. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011; 57(11): 1314–1322.
  5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1): 193–202.
  6. Ng J, Foin N, Ang HY, et al. Over-expansion capacity and stent design model: An update with contemporary DES platforms. Int J Cardiol. 2016; 221: 171–179.
  7. Institute of Laboratory Animal Resources NRC. Principles of Care of Laboratory Animals. NIH Publication. No. 85–23 1996.
  8. Foin N, Sen S, Allegria E, et al. Maximal expansion capacity with current DES platforms: a critical factor for stent selection in the treatment of left main bifurcations? EuroIntervention. 2013; 8(11): 1315–1325.
  9. Sperling C, Waliszewski MW, Kherad B, et al. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Ther Adv Cardiovasc Dis. 2019; 13: 1753944719826335.
  10. Lim KS, Jeong MHo, Bae InHo, et al. Histopathological comparison among biolimus, zotarolimus and everolimus-eluting stents in porcine coronary restenosis model. Korean Circ J. 2013; 43(11): 744–751.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl